open access

Vol 20, No 1-2 (2018)
Review articles
Get Citation

An assessment of the renal failure in vascular patients including the post-contrast kidney injury in the patients undergoing vascular diagnostic and treatment procedures

Wojciech Żelawski, Wacław Kuczmik, Grzegorz Biolik, Krzysztof Ziaja
Chirurgia Polska 2018;20(1-2):41-45.

open access

Vol 20, No 1-2 (2018)
Review articles

Abstract

Acute renal failure is one of the most important complications of the vascular and radiological procedures. An increasing number of the patients undergoing contrast based procedures, advanced and increasing age of the population as well as presence of diabetes and common use of the radiological procedures in many medicine disciplines implicates the need of the pre- and postprocedure control of the renal function. The literature described rate of the acute renal failure related to the contrast administration ranges from 1–13% depending on the treated population. In the paper the literature review concerning the risk of renal failure as well as its protection possibilities in the patients undergoing vascular contrast based procedures are presented. The review was supported by own authors observations. The risk assessment as well as renal failure complication prevention after vascular procedures should be an integral element of the qualification as well as perioperative management.

Abstract

Acute renal failure is one of the most important complications of the vascular and radiological procedures. An increasing number of the patients undergoing contrast based procedures, advanced and increasing age of the population as well as presence of diabetes and common use of the radiological procedures in many medicine disciplines implicates the need of the pre- and postprocedure control of the renal function. The literature described rate of the acute renal failure related to the contrast administration ranges from 1–13% depending on the treated population. In the paper the literature review concerning the risk of renal failure as well as its protection possibilities in the patients undergoing vascular contrast based procedures are presented. The review was supported by own authors observations. The risk assessment as well as renal failure complication prevention after vascular procedures should be an integral element of the qualification as well as perioperative management.
Get Citation

Keywords

vascular diseases, diagnostics, endovascular provcedures, contrast, renal failure

About this article
Title

An assessment of the renal failure in vascular patients including the post-contrast kidney injury in the patients undergoing vascular diagnostic and treatment procedures

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 20, No 1-2 (2018)

Pages

41-45

Bibliographic record

Chirurgia Polska 2018;20(1-2):41-45.

Keywords

vascular diseases
diagnostics
endovascular provcedures
contrast
renal failure

Authors

Wojciech Żelawski
Wacław Kuczmik
Grzegorz Biolik
Krzysztof Ziaja

References (33)
  1. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997; 103(5): 368–375.
  2. Roy AK, Mc Gorrian C, Treacy C, et al. A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. Cardiorenal Med. 2013; 3(1): 26–37.
  3. Ratanarat R, Skulratanasak P, Tangkawattanakul N, et al. Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for predicting hospital mortality in critically ill patients with multi-organ dysfunction syndrome. J Med Assoc Thai. 2013; 96(Suppl 2): S224–S231.
  4. ACR Committee on Drugs, Manual on contrast media, version 9, 2013. http://www.acr.org/Quality-Safety/Resources/Contrast-Manual (13.04.2018).
  5. Acute Kidney Injury Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) — clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2: 1–138.
  6. Bruce RJ, Djamali A, Shinki K, et al. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. AJR Am J Roentgenol. 2009; 192(3): 711–718.
  7. Mitchell AM, Jones AE, Tumlin JA, et al. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol. 2010; 5(1): 4–9.
  8. Khamaisi M, Raz I, Shilo V, et al. Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney Int. 2008; 74(1): 91–100.
  9. Kolonko A, Kokot F, Wiecek A. Contrast-associated nephropathy--old clinical problem and new therapeutic perspectives. Nephrol Dial Transplant. 1998; 13(3): 803–806.
  10. Morcos SK. Contrast media-induced nephrotoxicity — questions and answers. Br J Radiol. 1998; 71(844): 357–365.
  11. Rotter A. New contraindication to intravascular iodinated contrast material. Radiology. 1995; 197(2): 545–546.
  12. Bainey KR, Rahim S, Etherington K, et al. CAPTAIN Investigators. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial. Am Heart J. 2015; 170(1): 110–116.
  13. Byrd L, Sherman RL. Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review. Medicine (Baltimore). 1979; 58(3): 270–279.
  14. McDonald JS, Leake CB, McDonald RJ, et al. Acute kidney injury after intravenous versus intra-arterial contrast material administration in a paired cohort. Invest Radiol. 2016; 51(12): 804–809.
  15. Sigterman TA, Bolt LJJ, Krasznai AG, et al. Loss of kidney function after endovascular treatment of peripheral arterial disease. Ann Vasc Surg. 2017; 40: 231–238.
  16. Srodon P, Matson M, Ham R. Contrast nephropathy in lower limb angiography. Ann R Coll Surg Engl. 2003; 85(3): 187–191.
  17. Gao F, Zhou YuJ, Zhu Xi, et al. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Am J Nephrol. 2011; 34(3): 203–210.
  18. Kurihara O, Takano M, Uchiyama S, et al. Microvascular resistance in response to iodinated contrast media in normal and functionally impaired kidneys. Clin Exp Pharmacol Physiol. 2015; 42(12): 1245–1250.
  19. Sendeski M, Patzak A, Persson PB. Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, nonionic, monomeric and dimeric agents. Invest Radiol. 2010; 45(8): 453–457.
  20. Wybraniec MT, Bożentowicz-Wikarek M, Chudek J, et al. Pre-procedural renal resistive index accurately predicts contrast-induced acute kidney injury in patients with preserved renal function submitted to coronary angiography. Int J Cardiovasc Imaging. 2017; 33(5): 595–604.
  21. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014; 63(1): 71–79.
  22. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003; 181(6): 1463–1471.
  23. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl. 2006; 100: S16–S19.
  24. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291(19): 2328–2334.
  25. Navaneethan SD, Singh S, Appasamy S, et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009; 53(4): 617–627.
  26. Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004; 65(4): 1366–1374.
  27. Zhou Li, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med. 2012; 51(6): 531–535.
  28. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002; 223(3): 772–779.
  29. Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation. 2012; 126(3): 296–303.
  30. Wu YN, Yu H, Zhu XH, et al. Noninvasive delayed limb ischemic preconditioning attenuates myocardial ischemia-reperfusion injury in rats by a mitochondrial K(ATP) channel-dependent mechanism. Physiol Res. 2011; 60(2): 271–279.
  31. Gassanov N, Nia AM, Caglayan E, et al. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J Am Soc Nephrol. 2014; 25(2): 216–224.
  32. Menting TP, Sterenborg TB, de Waal Y, et al. Remote ischemic preconditioning to reduce contrast-induced nephropathy: study protocol for a randomized controlled trial. Trials. 2014; 15(4): 119–532.
  33. Fujihara M, Kawasaki D, Shintani Y, et al. CO2 Angiography Registry Investigators. Endovascular therapy by CO2 angiography to prevent contrast-induced nephropathy in patients with chronic kidney disease: a prospective multicenter trial of CO2 angiography registry. Catheter Cardiovasc Interv. 2015; 85(5): 870–877.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl